Full Text:   <279>

CLC number: 

On-line Access: 2023-01-04

Received: 2022-07-31

Revision Accepted: 2022-12-11

Crosschecked: 0000-00-00

Cited: 0

Clicked: 239

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 1998 Vol.-1 No.-1 P.

http://doi.org/10.1631/jzus.B2200385


Suppression of NLRP3 inflammasome by ivermectin ameliorates bleomycin-induced pulmonary fibrosis


Author(s):  Mai A. Abd-Elmawla, Heba R. Ghaiad, Enas S. Gad, Kawkab A. Ahmed, Maha Abdelmonem

Affiliation(s):  Department of Biochemistry, Faculty of Pharmacy, Cairo University, Egypt; more

Corresponding email(s):   heba.mosalam@pharma.cu.edu.eg, mei.abdelmawla@pharma.cu.edu.eg

Key Words:  Intratracheal instillation, Immunohistochemical, TGF-β, 1, NF-κ, B, Antifibrotic


Share this article to: More |Next Article >>>

Mai A. Abd-Elmawla, Heba R. Ghaiad, Enas S. Gad, Kawkab A. Ahmed, Maha Abdelmonem. Suppression of NLRP3 inflammasome by ivermectin ameliorates bleomycin-induced pulmonary fibrosis[J]. Journal of Zhejiang University Science B, 1998, -1(-1): .

@article{title="Suppression of NLRP3 inflammasome by ivermectin ameliorates bleomycin-induced pulmonary fibrosis",
author="Mai A. Abd-Elmawla, Heba R. Ghaiad, Enas S. Gad, Kawkab A. Ahmed, Maha Abdelmonem",
journal="Journal of Zhejiang University Science B",
volume="-1",
number="-1",
pages="",
year="1998",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2200385"
}

%0 Journal Article
%T Suppression of NLRP3 inflammasome by ivermectin ameliorates bleomycin-induced pulmonary fibrosis
%A Mai A. Abd-Elmawla
%A Heba R. Ghaiad
%A Enas S. Gad
%A Kawkab A. Ahmed
%A Maha Abdelmonem
%J Journal of Zhejiang University SCIENCE B
%V -1
%N -1
%P
%@ 1673-1581
%D 1998
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2200385

TY - JOUR
T1 - Suppression of NLRP3 inflammasome by ivermectin ameliorates bleomycin-induced pulmonary fibrosis
A1 - Mai A. Abd-Elmawla
A1 - Heba R. Ghaiad
A1 - Enas S. Gad
A1 - Kawkab A. Ahmed
A1 - Maha Abdelmonem
J0 - Journal of Zhejiang University Science B
VL - -1
IS - -1
SP -
EP -
%@ 1673-1581
Y1 - 1998
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2200385


Abstract: 
Ivermectin is an FDA-approved antiparasitic agent with antiviral and anti-inflammatory properties. Although recent studies reported the possible anti-inflammatory activity of ivermectin in respiratory injuries, its potential therapeutic effect on pulmonary fibrosis (PF) has not been investigated. The present study aimed to explore the ability of ivermectin (0.6 mg/kg) to alleviate bleomycin-induced biochemical derangements and histological changes in an experimental PF rat model. This can provide the means to validate the clinical utility of ivermectin as a treatment option for idiopathic PF. The results showed that ivermectin mitigates the bleomycin-evoked pulmonary injury, as manifested by the reduced infiltration of inflammatory cells, as well as decreased the inflammation and fibrosis scores. Intriguingly, ivermectin decreased collagen fiber deposition and suppressed transforming growth factor-beta (b2%29&ck%5b%5D=abstract&ck%5b%5D=keyword'>b>TGF-b2;b%5D=abstract&ck%5b%5D=keyword'>b>1) and fibronectin protein expressions, highlighting its anti-fibrotic activity. The current study revealed for the first time that ivermectin can suppress the NOD-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome, as manifested by the reduced gene expression of NLRP3 and the apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), with a subsequent decline in the interleukin b%5D=abstract&ck%5b%5D=keyword'>b>1b2; level. In addition, ivermectin inhibited the expression of intracellular nuclear transcription factor kappa b (bA%29&ck%5b%5D=abstract&ck%5b%5D=keyword'>b>NF-bA;b) and hypoxia b%5D=abstract&ck%5b%5D=keyword'>b>1b%5D=abstract&ck%5b%5D=keyword'>b>1;inducible factor b%5D=abstract&ck%5b%5D=keyword'>b>1b%5D=abstract&ck%5b%5D=keyword'>b>1;b%5D=abstract&ck%5b%5D=keyword'>b>1bb%5D=abstract&ck%5b%5D=keyword'>b>1; (HIF-b%5D=abstract&ck%5b%5D=keyword'>b>1bb%5D=abstract&ck%5b%5D=keyword'>b>1;) proteins along with lowering the oxidative stress and apoptotic markers. Altogether, the present study revealed that ivermectin could ameliorate pulmonary inflammation and fibrosis induced by bleomycin. These beneficial effects were mediated, at least partly, via the downregulation of b2%29&ck%5b%5D=abstract&ck%5b%5D=keyword'>b>TGF-b2;b%5D=abstract&ck%5b%5D=keyword'>b>1 and fibronectin, as well as the suppression of NLRP3 inflammasome through modulating HIF b%5D=abstract&ck%5b%5D=keyword'>b>1b%5D=abstract&ck%5b%5D=keyword'>b>1;b%5D=abstract&ck%5b%5D=keyword'>b>1bb%5D=abstract&ck%5b%5D=keyword'>b>1; and bA%29&ck%5b%5D=abstract&ck%5b%5D=keyword'>b>NF-bA;b expressions.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2023 Journal of Zhejiang University-SCIENCE